Treatment of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity

Area of Science:

• Immunotherapy
• Oncology
• Cellular Therapy

Background:

• Chimeric antigen receptor (CAR) T-cell therapy shows success in B-cell malignancies.
• BCMA-targeted CAR T-cells offer promise for multiple myeloma but lack durability.
• Need for novel targets and improved CAR T-cell strategies in multiple myeloma.

Purpose of the Study:

• Develop and evaluate a dual-CAR T-cell therapy targeting two multiple myeloma-associated antigens.
• Assess the safety and efficacy of this dual-CAR approach.
• Reduce off-target toxicity by targeting coexpressed antigens.

Main Methods:

• Designed a dual-CAR construct targeting CD138 and CD38 antigens (dCAR138-38).
• Evaluated dCAR138-38 efficacy and specificity in vitro.
• Assessed in vivo efficacy in NSG mice xenograft model of multiple myeloma.

Main Results:

• dCAR138-38 demonstrated potent anti-multiple myeloma responses in vitro and in vivo.
• Median survival in treated mice increased to 97 days from 31 days in controls.
• dCAR138-38 showed enhanced specificity for dual-antigen-expressing cells and low toxicity to healthy tissues.

Conclusions:

• The CD138/CD38-targeted dual CAR (dCAR138-38) is a potent and safe therapeutic strategy.
• Dual-targeting enhances specificity and reduces off-target effects in multiple myeloma immunotherapy.
• dCAR138-38 represents a promising alternative therapy for multiple myeloma patients.